Notice NOT-GM-25-004 from the NIH Guide for Grants and Contracts

Notice NOT-HG-25-010 from the NIH Guide for Grants and Contracts

Notice NOT-DA-25-034 from the NIH Guide for Grants and Contracts

Notice NOT-AI-24-082 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-MH-25-206 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) focuses on understanding bidirectional relationships between social media use and adolescent mental health, psychiatric symptoms, and risk or resilience for psychopathology. For the purposes of this NOFO, social media are defined as internet-based communication platforms and applications that enable interactions between users by sharing or consuming information. The NOFO focuses on adolescents (broadly defined here as 10-20 years of age), who have increasing access to social media and greater autonomy in their use of digital platforms. No effectiveness/efficacy trials will be accepted.

Funding Opportunity RFA-MH-25-205 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) focuses on understanding bidirectional relationships between social media use and adolescent mental health, psychiatric symptoms, and risk or resilience for psychopathology. For the purposes of this NOFO, social media are defined as internet-based communication platforms and applications that enable interactions between users by sharing or consuming information. The NOFO focuses on adolescents (broadly defined here as 10-20 years of age), who have increasing access to social media and greater autonomy in their use of digital platforms. No effectiveness/efficacy trials will be accepted.

Funding Opportunity PAR-25-119 from the NIH Guide for Grants and Contracts. Through this Notice of Funding Opportunity (NOFO) is to request applications that propose mechanistic investigations of the links between diet, lipid metabolism and tumor growth and progression. It is anticipated that this program will support fundamental studies designed to identify and define the molecular mechanisms through which lipid metabolism mediates tumor growth and progression, focusing specifically on the central role lipids play in linking diet with the biology of cancer; bridge the historically divided fields of nutrition and molecular metabolism; and stimulate research and tool development in this emerging area, which faces particular challenges because of the complexity of lipid biochemistry.

Funding Opportunity PAR-24-312 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) encourages cooperative agreement applications for investigator-initiated, multi-site, clinical trials (Phase III and beyond) to study the effects of natural products (i.e. botanicals, probiotics, and products marketed as dietary supplements) in NCCIH designated areas of high research priority. For this NOFO, natural products include promising nutritional regimens that standardize the amount of a specific naturally occurring nutritional compound (e.g., omega-3 fatty acids, anthocyanidins, or polyphenols) and have compelling preliminary evidence. Applicants should describe plans for a Clinical Coordinating Center to develop and implement the proposed multi-site clinical trial. The objective of the Clinical Coordinating Center application is to provide the scientific rationale and a comprehensive scientific and operational plan for the clinical trial. Clinical Coordinating Center applications are expected to describe plans for project management, participant recruitment and retention strategies, performance milestones, scientific conduct, and dissemination of results. Clinical Coordinating Center applications submitted under this NOFO will utilize a two-phase, milestone-driven, cooperative agreement (UG3/UH3) funding mechanism. In addition, an accompanying Data Coordinating Center application, submitted under PAR-24-125, proposing a data analysis and data management plan for the clinical project is required. Both a Clinical Coordinating Center application and a corresponding Data Coordinating Center (DCC) application need to be submitted simultaneously for consideration by NCCIH. For additional information about the mission, strategic vision, and research priorities of the NCCIH, applicants are encouraged to consult the NCCIH website: (https://nccih.nih.gov/about/plans).

Funding Opportunity RFA-DA-25-068 from the NIH Guide for Grants and Contracts. The scientific objective of this Notice of Funding Opportunity is to encourage research to delineate the role of inflammasomes in the neuropathology produced by acute or chronic drug exposure and HIV infection. Understanding the involvement of inflammasomes in virus and drug-induced immune activation may help identify molecular markers and CNS immune cells associated with HIV-1 infection or disease progression among substance abuse populations, as well as identify novel therapies to target inflammasome activation or suppression to treat neuroinflammation and immune dysregulation aroused in these processes.

Funding Opportunity RFA-DA-25-069 from the NIH Guide for Grants and Contracts. The scientific objective of this Notice of Funding Opportunity is to encourage research to delineate the role of inflammasomes in the neuropathology produced by acute or chronic drug exposure and HIV infection. Understanding the involvement of inflammasomes in virus and drug-induced immune activation may help identify molecular markers and CNS immune cells associated with HIV-1 infection or disease progression among substance abuse populations, as well as identify novel therapies to target inflammasome activation or suppression to treat neuroinflammation and immune dysregulation aroused in these processes.

Notice NOT-GM-25-002 from the NIH Guide for Grants and Contracts

Notice NOT-OD-24-180 from the NIH Guide for Grants and Contracts

Notice NOT-DA-24-053 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-25-053 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to encourage investigators to pursue translational activities and small clinical studies to advance the development of therapeutic, and diagnostic devices for disorders that affect the nervous or neuromuscular systems. Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities, obtaining an Investigational Device Exemption (IDE) for a Significant Risk (SR) study or Institutional Review Board (IRB) approval for a Non-Significant Risk (NSR) study, as well as a subsequent small clinical study. The clinical study is expected to provide information about the device function or final design that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. This NOFO is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in negotiating the final project plan before award and monitoring of research progress.

Notice NOT-DA-25-033 from the NIH Guide for Grants and Contracts

Notice NOT-CA-25-004 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-25-144 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to support studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, sustainability, scale-up, and spread of evidence-based interventions, practices, programs, tools, treatments, guidelines, and policies (hereafter referred to as evidence-based interventions).Studies that promote equitable dissemination and implementation of evidence-based interventions among underrepresented communities are encouraged. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (de-implement) the use of practices that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. Applications that focus on re-implementation of evidence-based health services that may be disrupted amidst disasters (e.g., pandemics, climate change) remain relevant. All applications must be within the scope of the mission of one of the Institutes/Centers listed above.

Funding Opportunity PAR-25-131 from the NIH Guide for Grants and Contracts. NLM wishes to accelerate access to, and availability of, secure, complete datasets and computational models that can serve as the basis for transformative biomedical discoveries. Innovative at-scale computational approaches that increase the speed and scope of curation processes are needed for data mining and knowledge discovery from growing quantities of biomedical data being produced from ongoing data science advances.

Funding Opportunity PAR-24-265 from the NIH Guide for Grants and Contracts. The Shared Instrument Grant (SIG) Program encourages applications from groups of NIH-supported investigators to purchase or upgrade a single item of high-priced, specialized, commercially available instruments or integrated instrumentation system. The minimum award is $50,000. There is no maximum price limit for the instrument; however, the maximum award is $750,000. Instruments supported include, but are not limited to: light microscopes, biomedical imagers, mass spectrometers, nuclear magnetic resonance spectrometers, flow cytometers, DNA and protein sequencers, biosensors, and X-ray diffractometers.

Funding Opportunity PAR-24-264 from the NIH Guide for Grants and Contracts. The High-End Instrumentation (HEI) Grant Program encourages applications from groups of NIH-supported investigators to purchase or upgrade a single item of high-end, specialized, commercially available instruments or integrated systems. The minimum award is $750,001. There is no maximum price limit for the instrument; however, the maximum award is $2,000,000. Instruments supported include, but are not limited to, nuclear magnetic resonance spectrometers, X-ray diffractometers, mass spectrometers, high throughput robotic screening systems, DNA and protein sequencers, biosensors, electron and light microscopes, flow cytometers, and biomedical imagers.